Abstract
Abstract Background: The goal of this study was to develop a novel drug delivery system (NDDS) of lamivudine (LAM) to overcome some drawbacks associated with LAM short half-life. To fulfill this goal, polymeric
Highlights
The goal of this study was to develop a novel drug delivery system (NDDS) of lamivudine (LAM) to overcome some drawbacks associated with LAM short half-life
A novel approach involving LAM-loaded nanoparticles and MNs insertion was used as a NDDS to enhance transdermal delivery of small molecular weight drugs across the skin layers [6]
LAM was kindly supplied by EVA Pharm pharmaceutical Co., Cairo, Egypt, polylactic-co-glycolic acid (PLGA) (LA:GA=75:25) (Purasorb PDLGA® 75/25, molecular weight of 10,000) was obtained from Purac Biomaterials, Holland, Bovine serum albumin (BSA) was purchased from MP Biomedical LLC, France, Dichloromethan was obtained from ADWIC, Egypt
Summary
The goal of this study was to develop a novel drug delivery system (NDDS) of lamivudine (LAM) to overcome some drawbacks associated with LAM short half-life. To fulfill this goal, polymeric LAM-loaded nanoparticles were prepared and their transdermal deliveries via passive and microneedles (MNs)-mediated transport were investigated. A novel approach involving LAM-loaded nanoparticles and MNs insertion was used as a NDDS to enhance transdermal delivery of small molecular weight drugs across the skin layers [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
